Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Imugene ( (AU:IMU) ) is now available.
Imugene Limited announced the successful outcomes of its Extraordinary General Meeting, where all resolutions were passed. This development underscores the company’s strategic direction and commitment to advancing its immuno-oncology therapies, potentially strengthening its position in the rapidly evolving cancer treatment market.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene is a clinical stage immuno-oncology company focused on developing innovative immunotherapies designed to activate cancer patients’ immune systems to target and eliminate tumors. Their pipeline includes an off-the-shelf CAR T cell therapy targeting blood cancers and oncolytic virotherapy for various cancers, in collaboration with standard care drugs and emerging therapies.
Average Trading Volume: 1,569,283
Technical Sentiment Signal: Sell
Current Market Cap: A$86.55M
For detailed information about IMU stock, go to TipRanks’ Stock Analysis page.